Eli Lilly’s Lyumjev Wins FDA Approval for Use in Insulin Pumps

Eli Lilly’s injectable insulin Lyumjev has won an expanded FDA indication for continuous subcutaneous infusion using an insulin pump.

The approval was supported by a phase 3 study showing Lyumjev, a specific formulation of insulin lispro, when delivered via insulin pump in adults with type 1 diabetes, was noninferior to Lilly’s injectable insulin Humalog.

Lyumjev first received FDA approval in June 2020 to reduce blood sugar levels and accelerate insulin uptake following meals in adults with type 1 and 2 diabetes.